Emcure Pharma Q1 2026: Profit Surges 63%, Sales Up 32%
By ThePip Desk
Emcure Pharma’s Q1 FY26 results show a remarkable 62.97% surge in Profit After Tax and a 32.32% increase in sales, reaching Rs. 2001.08M and Rs. 14509.31M respectively.
Emcure Pharma has announced a substantial financial performance for the June 2026 quarter, with its Profit After Tax (PAT) experiencing a sharp rise. The company’s sales also saw a significant increase compared to the corresponding period last year.
The company’s sales for the June 2026 quarter reached Rs. 14509.31 millions, marking a 32.32% increase from Rs. 10965.73 millions recorded in the June 2025 quarter. This robust revenue growth underpinned the overall positive results.
Profit After Tax for the quarter ended June 2026 stood at Rs. 2001.08 millions. This figure represents a considerable 62.97% growth from Rs. 1227.89 millions reported in the same quarter of the previous fiscal year.
Operating profit, or PBIDT, also demonstrated strong momentum, rising to Rs. 3646.15 millions for the June 2026 quarter. This compares favorably to Rs. 2495.24 millions from the corresponding June 2025 quarter, indicating improved operational efficiency.
Detailed Financial Overview
Other Income contributed Rs. 250.32 millions to the quarter’s earnings, an increase of 16.30% from Rs. 215.24 millions previously. Meanwhile, Interest expenses rose by 59.59% to Rs. 327.76 millions from Rs. 205.38 millions.
Profit Before Depreciation, Interest, and Tax (PBDT) reached Rs. 3318.39 millions for the quarter. This marks a 47.17% surge from Rs. 2254.86 millions in the June 2025 quarter, reflecting enhanced profitability before non-cash charges and financing costs.
Depreciation increased by 5.60% to Rs. 631.66 millions, up from Rs. 598.17 millions in the prior year’s quarter. Despite this, Profit Before Tax (PBT) showed significant growth, reaching Rs. 2686.73 millions.
The PBT figure represents a 62.17% jump from Rs. 1656.69 millions in the June 2025 quarter, underscoring Emcure Pharma’s strong financial trajectory. The company’s performance highlights a period of accelerated growth across key financial metrics.